Utility of the “Modified Erasmus GBS Respiratory Insufficiency Score” in Axonal and Demyelinating Guillain–Barré Syndrome

Documenti analoghi

• Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial
  di: Satoshi Kuwabara, et al.
  Pubblicazione: (2024)
• Unveiling a Regional Variant of Demyelinating Guillain–Barré Syndrome: Nerve Conduction Study Evidence in Bifacial Weakness With Paresthesias
  di: Jin Song, et al.
  Pubblicazione: (2026)
• GDAP1‐Related Charcot–Marie–Tooth Disease: Axonal or Demyelinating Subtype? Autosomal Recessive or Autosomal Dominant Inheritance?
  di: Moez Ravanbod, et al.
  Pubblicazione: (2025)
• Altered Cellular Pathways in the Blood of Patients With Guillain‐Barre Syndrome
  di: Marília Fabiana de Oliveira Lima, et al.
  Pubblicazione: (2025)
• Patient‐Reported Outcome Measures for Assessing Health‐Related Quality of Life in Patients With Polyneuropathies, Focusing on Guillain‐Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy: A Systematic Review of Measurement Properties
  di: Farah Pelouto, et al.
  Pubblicazione: (2025)